Last updated: 02/24/2020 18:00:10
An observational study to determine the correlation between MAGE-A3, PRAME polymorphism and expression levels of MAGE-A3 and PRAME in NSCLC patients in Taiwan (NOT FINAL TITLE)
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An observational study to determine the correlation between MAGE-A3, PRAME polymorphism and expression levels of MAGE-A3 and PRAME in NSCLC patients in Taiwan (NOT FINAL TITLE)
Trial description: An observational study to determine the correlation between MAGE-A3, PRAME polymorphism and expression levels of MAGE-A3 and PRAME in NSCLC patients in Taiwan (NOT FINAL TITLE)
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Pan SH et al. (2016) Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non–small cell lung cancer patients. Asia Pac J Clin Oncol. doi: 10.1111/ajco.12586. [Epub ahead of print]
Medical condition
Immunologic Tests
Product
GSK1711805A
Collaborators
Not applicable
Study date(s)
August 2011 to November 2013
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2013-14-11
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website